Opinion

Video

Factors Informing Individualized Treatment Decision-Making for HER2-Positive Metastatic Breast Cancer

Author(s):

Sara M. Tolaney, MD, MPH

Sara M. Tolaney, MD, MPH explains that treatment decisions for metastatic breast cancer are based on the current biopsy showing receptor status, but prior biopsies over the full course of disease are considered as well, particularly for HER2 targeted therapies which may work even if HER2 low expression occurred years earlier.

Related Videos
Image of man with grey hair.
Image of woman with blonde hair.
Image of woman with brown hair.
Image of a woman with wavy blonde hair wearing glasses.
Image of a woman with tied back hair, wearing pearl earrings.
Image of a woman with layered hair, wearing a bright blue cardigan.
Image of a woman wearing a red tank top.
Image of Annie Bond.
Image of a man with rectangular glasses and short dark hair.
Related Content
Image of woman holding a pink ribbon.
December 20th 2024

Low ctDNA Levels May Show Longer Recurrence-Free Interval in Breast Cancer

Spencer Feldman
In patients with triple-negative breast cancer, ctDNA was most commonly identified within six months after treatment, reflecting the disease’s typical pattern of early recurrence.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Illustration of a breast with a tumor up close.
December 19th 2024

Enhertu May Help Preserve Quality of Life in HER2-Positive Breast Cancer

Kyle Doherty
Treatment with Enhertu showed favorable outcomes regarding health-related quality of life in patients with HER2-positive breast cancer, regardless of brain metastases.
Cancer Horizons podcast logo
December 12th 2023

Conference Highlights from SABCS

Alex Biese Brielle Benyon
CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.
Image of question marks.
December 16th 2024

Delivering Answers to Pressing Questions About Cancer

Mike Hennessy Jr.
At CURE, we remain steadfastly dedicated to providing our readers with answers about cancer research.
Illustration of body.
December 16th 2024

Camrelizumab Plus Chemo May Be New Presurgical Option in Breast Cancer Subset

Kristi Rosa
Presurgical camrelizumab plus chemotherapy significantly improved responses versus chemotherapy alone in early or locally advanced TNBC.